Literature DB >> 324678

C1q binding substances in pemphigus and bullous pemphigoid. Detection with a [131I] C1q binding assay.

G Tappeiner, K G Heine, J C Kahl, R E Jordon.   

Abstract

A modification of the [125I]C1q binding assay was developed to allow the estimation of C1q binding activity (C1q BA) in pemphigus and bullous pemphigoid sera. The modifications include lower final concentration of PEG 6000 (1-5%) which permitted the use of sera that had been stored at -20 degrees C for extended periods of time; use of 131I instead of 125I and an [131I] C1q concentration of 5 microng/ml rather than 1 microng/ml. EDTA was used at a final concentration of 0-13 M to obviate the need for heat inactivation of sera. Sera from seventy-one patients with pemphigus and from 142 patients with bullous pemphigoid were tested for C1q BA. Of these 40% of the pemphigus and 20% of the bullous pemphigoid patients showed elevated C1q BA. A relationship between elevated C1q BA in serum and active disease was noted. Sequential samples from forty patients with pemphigus and thirty-seven patients with bullous pemphigoid demonstrated two different types of relationship between serum antibody titres to cutaneous antigens and C1a BA. In some patients serum antibody titres and C1q BA increased and decreased simultaneously; in others, increase of C1q BA followed increase of antibody titre and coincided with its decrease. The latter relationship supports the hypothesis that C1q BA may represent at least in part antigen-antibody complexes containing cutaneous antigens.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324678      PMCID: PMC1540889     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  DEMONSTRATION OF SKIN ANTIBODIES IN SERA OF PEMPHIGUS VULGARIS PATIENTS BY INDIRECT IMMUNOFLUORESCENT STAINING.

Authors:  E H BEUTNER; R E JORDON
Journal:  Proc Soc Exp Biol Med       Date:  1964-11

2.  AUTOANTIBODIES IN PEMPHIGUS VULGARIS: RESPONSE TO AN INTERCELLULAR SUBSTANCE OF EPIDERMIS.

Authors:  E H BEUTNER; W F LEVER; E WITEBSKY; R JORDON; B CHERTOCK
Journal:  JAMA       Date:  1965-05-24       Impact factor: 56.272

3.  CHARACTERIZATION OF A HUMAN MACROGLOBULIN. I. THE MOLECULAR WEIGHT OF ITS SUBUNIT.

Authors:  F MILLER; H METZGER
Journal:  J Biol Chem       Date:  1965-08       Impact factor: 5.157

4.  Effect of mercaptoethanol on complement binding ability of human 7 S gammaglobulin.

Authors:  G WIEDERMANN; P A MIESCHER; E C FRANKLIN
Journal:  Proc Soc Exp Biol Med       Date:  1963-07

5.  Basement zone antibodies in bullous pemphigoid.

Authors:  R E Jordon; E H Beutner; E Witebsky; G Blumental; W L Hale; W F Lever
Journal:  JAMA       Date:  1967-05-29       Impact factor: 56.272

6.  Studies on circulating immune complexes. 3. Factors governing the ability of circulating complexes to localize in blood vessels.

Authors:  C G Cochrane; D Hawkins
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

7.  Negative complement immunofluorescence in pemphigus.

Authors:  R E Jordon; W M Sams; G Diaz; E H Beutner
Journal:  J Invest Dermatol       Date:  1971-12       Impact factor: 8.551

8.  The complement system in bullous pemphigoid. II. Immunofluorescent evidence for both classical and alternate-pathway activation.

Authors:  R E Jordon; A L Schroeter; R A Good; N K Day
Journal:  Clin Immunol Immunopathol       Date:  1975-01

9.  Properties of soluble immune complexes.

Authors:  R W Lightfoot; R E Drusin; C L Christian
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

10.  Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion.

Authors:  V Agnello; R J Winchester; H G Kunkel
Journal:  Immunology       Date:  1970-12       Impact factor: 7.397

View more
  10 in total

Review 1.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

Review 2.  Pitfalls in the methodology for detection of immune complexes.

Authors:  R Heimer; S Per
Journal:  Surv Immunol Res       Date:  1982

Review 3.  Antibody-induced proteinase activation: a proposed mechanism for pemphigus.

Authors:  K H Singer; K Hashimoto; G S Lazarus
Journal:  Springer Semin Immunopathol       Date:  1981-06

Review 4.  Circulating immune complexes in dermatologic disease.

Authors:  T J Lawley; R P Hall
Journal:  Springer Semin Immunopathol       Date:  1981

5.  Serum and blister fluid immune complexes in bullous pemphigoid: detection with C1q and monoclonal rheumatoid factor.

Authors:  R E Jordon; M F Struve; L L Bushkell
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

6.  Circulating immune complexes in active Behçet's disease.

Authors:  R C Gupta; J D O'Duffy; F C McDuffie; M Meurer; R E Jordon
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

7.  Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.

Authors:  R C Gupta; F C McDuffie; G Tappeiner; R E Jordon
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

8.  Platelet-derived factors enhance pemphigus acantholysis in skin organ cultures.

Authors:  T Hunziker; U E Nydegger; P G Lerch; J D Vassalli
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

9.  Studies on circulating immune complexes of the liver disease. 4. Clq binding activity.

Authors:  T Arima; J Narumoto; H Shimomura; K Suwaki; K Kunishi; T Yasuhara; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1980

10.  Circulating immune complexes in cutaneous vasculitis. Detection with C1q and monoclonal rheumatoid factor.

Authors:  S E Mackel; G Tappeiner; H Brumfield; R E Jordan
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.